Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meperidine SCHEMBL9752749 | 0.90 | OPRM1 (0.74) | CHRM5CHRM3OPRM1SLC22A1SLC6A4 | |
| SCHEMBL6543304 | 0.83 | OPRM1 (0.56) | CHRM5CHRM3OPRM1HTTSMN1; SMN2 | |
| SCHEMBL28252205 | 0.81 | CHRM5 (0.47) | CHRM5CHRM3OPRM1HTTSMN1; SMN2 | |
| SCHEMBL6543328 | 0.81 | TSHR (0.61) | CHRM5CHRM3OPRD1OPRK1HTT | |
| SCHEMBL4913158 | 0.81 | ALDH1A1 (0.67) | CHRM5CHRM3OPRM1SLC22A1SLC6A4 | |
| SCHEMBL11637878 | 0.80 | OPRL1 (0.72) | CHRM5CHRM3ADRA1AHTTSMN1; SMN2 | |
| SCHEMBL16420404 | 0.80 | CNR1 (0.49) | CHRM5CHRM3OPRM1SLC22A1SLC6A4 | |
| SCHEMBL2472385 | 0.79 | OPRM1 (0.54) | CHRM5CHRM3OPRM1HTTSMN1; SMN2 | |
| SCHEMBL9064652 | 0.79 | OPRM1 (0.66) | OPRM1ADRA1AKCNH2OPRL1 | |
| SCHEMBL2468078 | 0.78 | TSHR (0.60) | CHRM5CHRM3OPRD1OPRK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3914246-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152212-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2020-07-30 | — | — | WO | disclosed |
| EP-0506778-B1 | SUBSTITUTED 4-PHENYL-4-PIPERIDINECARBOXAMIDES WITH BOTH LOCAL ANAESTHETIC AND ANALGESIC EFFECT AS WELL AS PROCESSES FOR THEIR PREPARATION | ASTRA AB (SE) | 1996-05-29 | — | — | EP | disclosed |
| US-5360805-A | Substituted 4-phenyl-4-piperidinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation | AKTIEBOLAGET ASTRA (SE) | 1994-11-01 | — | — | US | disclosed |
| US-5227389-A | SUBSTITUTED 4-PHENYL-4-PIPERIDINECARBOXAMIDES WITH BOTH LOCAL ANAESTHETIC AND ANALGESIC EFFECT AS WELL AS PROCESSES FOR THEIR PREPARATION | AKTIEBOLAGET ASTRA (SE) | 1993-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | FABP7, ALB, SLC1A2 | CHRM5 170/4885CHRM3 164/4885OPRM1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.